Organisation paid for research Program year 2025 Source: CMS Open Payments

QPS Miami Research Associates

Neither a doctor nor a teaching hospital

Research payments

$1,558,471

118 payments

Through program year 2025, QPS Miami Research Associates is reported as receiving $1,558,471 in research payments, across 118 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $110,706 5
2022 Research $20,359 2
2021 Research $676,264 7
2020 Research $313,940 45
2019 Research $437,202 59

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $948,066 92 payments
  2. Amgen Inc. $378,737 8 payments
  3. Supernus Pharmaceuticals, Inc. $100,575 8 payments
  4. GlaxoSmithKline, LLC. $69,968 5 payments
  5. AstraZeneca Pharmaceuticals LP $42,268 1 payment
  6. Ucb SA $15,462 3 payments
  7. Novartis Pharmaceuticals Corporation $3,395 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-RangingTrial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults $251,188 1 payment
  2. AMG 598 - Ph 1 Safety; Tolerability; PK and PD of MAD $221,289 2 payments
  3. Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE $221,048 7 payments
  4. A Phase 1,Phase 2, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Adults $218,892 7 payments
  5. Amg 890_Fih/ Sad $147,593 5 payments
  6. Screening Protocol for Epstein-Barr Virus Vaccine Studies $91,849 1 payment
  7. A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 One Year Later in Healthy Adults 50 Years of Age or Older PNEU-PATH $72,274 11 payments
  8. Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficit/Hyperactivity Disorder (Adhd) $64,498 6 payments
  9. Rabies Sam=Cne-001 $62,216 1 payment
  10. A Phase 1 Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of MEDI6570 in Subjects with Type 2 Diabetes Mellitus $42,268 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record